Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Roche

Status and phase: Completed; Phase 3

Conditions: Chronic Hepatitis B

Treatments: Drug: PEGASYS

Study type: Interventional

Funder types: Industry

Identifiers

NCT00048945

WV16240

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.

Enrollment: 820 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of hepatitis B
• Not pregnant

Exclusion criteria

• Treatment for hepatitis B in past 6 months
• Other hepatitis infections
• Severe liver disease
• Pregnancy